Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
2 evidence topics · 4 sources
Summary
Post-EGFR-TKI treatment options include amivantamab plus carboplatin and pemetrexed and, after prior EGFR-directed therapy and platinum chemotherapy, datopotamab deruxtecan. These options occupy different treatment positions. HARMONi compared ivonescimab plus chemotherapy with placebo plus chemotherapy, not with either of these active combination or antibody-drug conjugate strategies. Its results therefore do not establish superiority over those alternatives.